CardioDx expands C-suite team with new CFO and CMO
This article was originally published in Clinica
Cardiovascular genomic diagnostics firm CardioDx has expanded its executive team with two new appointments. Mark Monane joins the Palo Alto, California firm as chief medical officer, and Andrew Guggenhime joins as chief financial officer. Dr Monane was most recently managing director of equity research for Needham and Company, focusing on analyses of emerging biotech companies in the cardiovascular and cancer areas. Mr Guggenhime served as CFO at Calistoga Pharmaceuticals prior to joining CardioDx. In May, CardioDx closed a $60m financing round; the funds will be used to expand reimbursement coverage in the US for Corus CAD, the firm's gene expression test to help physicians determine if a patient has obstructive coronary artery disease.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.